News

New York Fed’s Tweak to Key Repo Facility Hampered by Its Design

(Bloomberg) -- The Federal Reserve Bank of New York’s plan to conduct additional liquidity operations through the end of the year will provide needed support at a time when funding markets tend to be volatile, though its current framework will limit the effectiveness of the measures. Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces L

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria